Network meta-analysis identifies concentration-dependent neuroprotective effects of GLP-1 and SGLT2 drugs on delirium, depression, dementia, and coma | Research

The takeaway

NMA reveals differential neuroprotective effects of individual GLP-1RAs and SGLT2i agents on delirium, depression, dementia, and coma, with concentration-dependent responses suggesting dose optimization could maximize neurological benefits.

Agent-specific brain protection
Not all GLP-1 drugs protect the brain equally—this NMA identifies which specific agents are best for delirium, depression, dementia, and coma at which concentrations

What the researchers found

Differential neuroprotective effects between individual GLP-1RAs and SGLT2i agents. Concentration-dependent responses identified. Four neurological outcomes: delirium, depression, dementia, coma. Agent-specific effects suggest personalized selection possible.

Why it matters

Not all GLP-1 drugs are equal for brain protection. Identifying which specific agents best protect against which neurological conditions enables precision prescribing for both metabolic and neurological benefit.

How the study worked

Network meta-analysis comparing individual GLP-1RA and SGLT2i agents for neurological outcomes (delirium, depression, dementia, coma).

What this study cannot tell us

NMA indirect comparisons. Neurological outcomes from diabetes trials (not primary endpoints). Concentration-dependency inferred from dose, not measured levels.

How to read the evidence

NMA of available clinical trial data. Novel precision approach.

When this study was published

Published in 2025.

The bigger picture

This moves beyond "GLP-1 drugs are neuroprotective" to "which GLP-1 drug is best for which neurological condition at which dose"—a precision medicine approach to neuroprotection.

Questions still open

Which GLP-1 drug is best for dementia prevention?
Do higher doses provide more neuroprotection or just more side effects?
Should neurological risk profiles guide diabetes drug selection?

Common questions

Are all GLP-1 drugs equally good for brain health?

No—this analysis found different GLP-1 drugs have different levels of protection against various brain conditions (delirium, depression, dementia). Some agents are better for certain conditions than others, and the benefit appears to depend on dose. This could help doctors choose the best drug for each patient's neurological risk.

Could my diabetes drug choice affect my brain health?

Yes. This study shows that specific GLP-1 and SGLT2 drugs have measurably different effects on brain outcomes. Choosing the right agent—and the right dose—could provide maximum neurological protection alongside metabolic benefits.

Read the original research

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.

Journal of the Royal Society of Medicine, 1410768251395877

View on PubMed ↗Publisher’s paper ↗

Citation

Tseng, Ping-Tao; Zeng, Bing-Yan; Hsu, Chih-Wei; Suen, Mein-Woei; Hung, Chao-Ming; Carvalho, Andre F; Stubbs, Brendon; Chen, Yen-Wen; Chen, Tien-Yu; Lei, Wei-Te; Lin, Pao-Yen; Chen, Jiann-Jy; Su, Kuan-Pin; Wang, Hung-Yu; Zeng, Bing-Syuan; Shiue, Yow-Ling; Liang, Chih-Sung. (2025). The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.. Journal of the Royal Society of Medicine, 1410768251395877. https://doi.org/10.1177/01410768251395877